We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
BiDil flops.
- Authors
Huggett, Brady
- Abstract
The article reports that the drug BiDil (isosorbide dinitrate and hydralazine hydrochloride) of the NitroMed of Lextington, Massachusetts has been a flop. According to the author, BiDil has been approved to treat congestive heart failure in self identified black patients. He added that the product is a fixed-dose combination two generics in which the exact mechanism by which they work together is unknown. Moreover, analyst with Pacific Growth Equities in San Francisco Liana Moussatos has stated that the product has been greatly affected in the marketplace with its generic ingredients being readily available at a fraction of the cost.
- Subjects
MASSACHUSETTS; CONGESTIVE heart failure; HEART diseases; ANTIHYPERTENSIVE agents; MEDICINE; GENERIC drugs; NITROMED Inc.; PACIFIC Growth Equities LLC; MOUSSATOS, Liana
- Publication
Nature Biotechnology, 2008, Vol 26, Issue 3, p252
- ISSN
1087-0156
- Publication type
Article
- DOI
10.1038/nbt0308-252b